GRFS / Grifols (GRFS) Upgraded to Strong Buy: Here's Why

Grifols, S.A. (NASDAQ:GRFS ) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Nuria Pascual - IR and Sustainability O more_horizontal

Grifols shares soared in early trading on Thursday after the Spanish drugmaker upgraded its annual profit outlook following a strong quarter. more_horizontal

Investors looking for stocks in the Medical - Drugs sector might want to consider either Grifols (GRFS) or Stevanato Group (STVN). But which of these more_horizontal

Grifols (GRFS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). more_horizontal

Grifols is a promising buy opportunity thanks to its potential to reduce its net debt/EBITDA ratio. The company's focus on deleveraging is showing res more_horizontal

I've reviewed Grifols once before and gave you my overall thesis on what I believe to be a solid pharma/biotech company. Investing in Spanish stocks w more_horizontal

Grifols, S.A. (NASDAQ:GRFS ) Q1 2023 Earnings Conference Call May 9, 2023 8:30 AM ET Company Participants Nuria Pascual - IR Thomas Glanzmann - Execut more_horizontal

Grifols' first-quarter report came a day after it announced a new leadership team. The company upgraded half-year and full-year guidance. more_horizontal